These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18645035)

  • 21. Testosterone, 7-benzyloxyquinoline, and 7-benzyloxy-4-trifluoromethyl-coumarin bind to different domains within the active site of cytochrome P450 3A4.
    Lu P; Lin Y; Rodrigues AD; Rushmore TH; Baillie TA; Shou M
    Drug Metab Dispos; 2001 Nov; 29(11):1473-9. PubMed ID: 11602524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites.
    Korzekwa KR; Krishnamachary N; Shou M; Ogai A; Parise RA; Rettie AE; Gonzalez FJ; Tracy TS
    Biochemistry; 1998 Mar; 37(12):4137-47. PubMed ID: 9521735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic interactions between the orexin receptor antagonist almorexant and the CYP3A4 inhibitors ketoconazole and diltiazem.
    Dingemanse J; Cruz HG; Gehin M; Hoever P
    J Pharm Sci; 2014 May; 103(5):1548-56. PubMed ID: 24604243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resolution of multiple substrate binding sites in cytochrome P450 3A4: the stoichiometry of the enzyme-substrate complexes probed by FRET and Job's titration.
    Fernando H; Halpert JR; Davydov DR
    Biochemistry; 2006 Apr; 45(13):4199-209. PubMed ID: 16566594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan.
    Bonn B; Masimirembwa CM; Castagnoli N
    Drug Metab Dispos; 2010 Jan; 38(1):187-99. PubMed ID: 19797609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modelling atypical CYP3A4 kinetics: principles and pragmatism.
    Houston JB; Galetin A
    Arch Biochem Biophys; 2005 Jan; 433(2):351-60. PubMed ID: 15581591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of luciferin-isopropyl acetal as a CYP3A4 substrate for human hepatocytes: effects of organic solvents, cytochrome P450 (P450) inhibitors, and P450 inducers.
    Li AP
    Drug Metab Dispos; 2009 Aug; 37(8):1598-603. PubMed ID: 19451401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nile Red is a fluorescent allosteric substrate of cytochrome P450 3A4.
    Lampe JN; Fernandez C; Nath A; Atkins WM
    Biochemistry; 2008 Jan; 47(2):509-16. PubMed ID: 18092806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition.
    Zhang X; Jones DR; Hall SD
    Drug Metab Dispos; 2009 Jan; 37(1):150-60. PubMed ID: 18854379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of isomeric testosterone dimers to explore allosteric effects in substrate binding to cytochrome P450 CYP3A4.
    Denisov IG; Mak PJ; Grinkova YV; Bastien D; Bérubé G; Sligar SG; Kincaid JR
    J Inorg Biochem; 2016 May; 158():77-85. PubMed ID: 26774838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allosteric effects on substrate dissociation from cytochrome P450 3A4 in nanodiscs observed by ensemble and single-molecule fluorescence spectroscopy.
    Nath A; Koo PK; Rhoades E; Atkins WM
    J Am Chem Soc; 2008 Nov; 130(47):15746-7. PubMed ID: 18980315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite.
    Zhang X; Quinney SK; Gorski JC; Jones DR; Hall SD
    Drug Metab Dispos; 2009 Aug; 37(8):1587-97. PubMed ID: 19420129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interaction.
    Wong SG; Fan PW; Subramanian R; Tonn GR; Henne KR; Johnson MG; Tadano Lohr M; Wong BK
    Drug Metab Dispos; 2010 May; 38(5):841-50. PubMed ID: 20100816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
    Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
    J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elucidating substrate promiscuity in the human cytochrome 3A4.
    Hayes C; Ansbro D; Kontoyianni M
    J Chem Inf Model; 2014 Mar; 54(3):857-69. PubMed ID: 24571781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New combined model for the prediction of regioselectivity in cytochrome P450/3A4 mediated metabolism.
    Oh WS; Kim DN; Jung J; Cho KH; No KT
    J Chem Inf Model; 2008 Mar; 48(3):591-601. PubMed ID: 18290640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Flexibility of human cytochrome P450 enzymes: molecular dynamics and spectroscopy reveal important function-related variations.
    Hendrychová T; Anzenbacherová E; Hudeček J; Skopalík J; Lange R; Hildebrandt P; Otyepka M; Anzenbacher P
    Biochim Biophys Acta; 2011 Jan; 1814(1):58-68. PubMed ID: 20656072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mixing apples and oranges: Analysis of heterotropic cooperativity in cytochrome P450 3A4.
    Frank DJ; Denisov IG; Sligar SG
    Arch Biochem Biophys; 2009 Aug; 488(2):146-52. PubMed ID: 19560436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gomisin A is a Novel Isoform-Specific Probe for the Selective Sensing of Human Cytochrome P450 3A4 in Liver Microsomes and Living Cells.
    Wu JJ; Ge GB; He YQ; Wang P; Dai ZR; Ning J; Hu LH; Yang L
    AAPS J; 2016 Jan; 18(1):134-45. PubMed ID: 26361765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
    Guo J; Zhou D; Li Y; Khanh BH
    Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.